Triplet Therapeutics was founded in 2018, with an initial focus on developing oligonucleotide therapies for repeat expansion disorders.  To conduct large screens of candidate compounds, we selected Horizon for their broad and flexible synthetic capabilities and responsive screening group.  Working together with screening and custom synthesis teams from concept through completion, we established an iterative process whereby rapid syntheses fueled screening efforts conducted and analyzed both internally and externally.  The two-way dynamic established between Triplet and Horizon was vigorous, informative, and aided both drug development and innovation in screening.  We are currently working on additional functional genomics screens as our partnership evolves.